These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8573955

  • 1. Vigabatrin-associated reversible acute psychosis in a child.
    Cánovas Martínez A, Ordovás Baines JP, Beltrán Marqués M, Escrivá Aparisi A, Delgado Cordón F.
    Ann Pharmacother; 1995 Nov; 29(11):1115-7. PubMed ID: 8573955
    [Abstract] [Full Text] [Related]

  • 2. [Acute psychosis and vigabatrin in childhood].
    Chiaretti A, Castorina M, Tortorolo L, Piastra M, Polidori G.
    Pediatr Med Chir; 1994 Nov; 16(5):489-90. PubMed ID: 7885961
    [Abstract] [Full Text] [Related]

  • 3. Vigabatrin and psychosis.
    Sander JW, Hart YM, Trimble MR, Shorvon SD.
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):435-9. PubMed ID: 1865207
    [Abstract] [Full Text] [Related]

  • 4. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome.
    Stuppaeck CH, Deisenhammer EA, Kurz M, Whitworth AB, Hinterhuber H.
    Alcohol Alcohol; 1996 Jan; 31(1):109-11. PubMed ID: 8672169
    [No Abstract] [Full Text] [Related]

  • 5. Status epilepticus during vigabatrin treatment: a report of three cases.
    de Krom MC, Verduin N, Visser E, Kleijer M, Scholtes F, De Groen JH.
    Seizure; 1995 Jun; 4(2):159-62. PubMed ID: 7670770
    [Abstract] [Full Text] [Related]

  • 6. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
    Srinivasan J, Richens A.
    Drug Saf; 1994 May; 10(5):395-405. PubMed ID: 8037889
    [Abstract] [Full Text] [Related]

  • 7. [New drugs in the treatment of childhood epilepsy: vigabatrin (study of 61 subjects)].
    Raucci U, Spalice A, Basile LA, Guardalà C, Nasta L, Terenzi S, Iannetti P.
    Pediatr Med Chir; 1994 May; 16(6):575-8. PubMed ID: 7708543
    [Abstract] [Full Text] [Related]

  • 8. The new anti-epileptic drugs.
    Murphy R.
    Ir Med J; 1995 May; 88(6):198-9. PubMed ID: 8575915
    [No Abstract] [Full Text] [Related]

  • 9. Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective.
    Schmidt D.
    Acta Neurol Scand Suppl; 1995 May; 162():7-10. PubMed ID: 7495192
    [Abstract] [Full Text] [Related]

  • 10. Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA).
    Matern D, Lehnert W, Gibson KM, Korinthenberg R.
    J Inherit Metab Dis; 1996 May; 19(3):313-8. PubMed ID: 8803774
    [Abstract] [Full Text] [Related]

  • 11. [Vigabatrin: results with a new antiepileptic agents in 57 patients in a general neurological practice].
    van der Zwan A, van der Zwan A.
    Ned Tijdschr Geneeskd; 1994 Sep 10; 138(37):1859-63. PubMed ID: 7935922
    [Abstract] [Full Text] [Related]

  • 12. [Vigabatrin--a new antiepileptic agent].
    Nakken KO, Henriksen O, Johannessen SI.
    Tidsskr Nor Laegeforen; 1994 Oct 10; 114(24):2843-4. PubMed ID: 7998031
    [Abstract] [Full Text] [Related]

  • 13. Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain.
    Sidhu RS, Del Bigio MR, Tuor UI, Seshia SS.
    Exp Neurol; 1997 Apr 10; 144(2):400-5. PubMed ID: 9168839
    [Abstract] [Full Text] [Related]

  • 14. [Acute psychotic disorder associated with vigabatrin].
    Xavier M, Bento MS, Pereira DP, De Almeida JM.
    Acta Med Port; 2000 Apr 10; 13(3):111-4. PubMed ID: 11026149
    [Abstract] [Full Text] [Related]

  • 15. Severe persistent visual field constriction associated with vigabatrin.
    Eke T, Talbot JF, Lawden MC.
    BMJ; 1997 Jan 18; 314(7075):180-1. PubMed ID: 9022432
    [No Abstract] [Full Text] [Related]

  • 16. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D.
    Ophthalmology; 1999 Sep 18; 106(9):1792-8. PubMed ID: 10485552
    [Abstract] [Full Text] [Related]

  • 17. Psychotic and severe behavioural reactions with vigabatrin: a review.
    Ferrie CD, Robinson RO, Panayiotopoulos CP.
    Acta Neurol Scand; 1996 Jan 18; 93(1):1-8. PubMed ID: 8825264
    [Abstract] [Full Text] [Related]

  • 18. [Vigabatrin: balancing effectiveness vs. (irreversible) visual field loss as a side effect].
    Hardus P, Engelsman M, van Veelen CW, Stilma JS.
    Ned Tijdschr Geneeskd; 2000 Oct 21; 144(43):2066-9. PubMed ID: 11072511
    [Abstract] [Full Text] [Related]

  • 19. Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
    Lambert MV, Bird JM.
    Seizure; 1997 Jun 21; 6(3):233-5. PubMed ID: 9203253
    [Abstract] [Full Text] [Related]

  • 20. Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group.
    Russ W.
    Schweiz Arch Neurol Psychiatr (1985); 1995 Jun 21; 146(2):55-9. PubMed ID: 7569836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.